170 related articles for article (PubMed ID: 37560303)
1. Organochlorine pesticides and epigenetic alterations in thyroid tumors.
Salimi F; Asadikaram G; Ashrafi MR; Zeynali Nejad H; Abolhassani M; Abbasi-Jorjandi M; Sanjari M
Front Endocrinol (Lausanne); 2023; 14():1130794. PubMed ID: 37560303
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
3.
Li J; Yin Y; Huang H; Li M; Li H; Zhang M; Jiang C; Yang R
Epigenomics; 2023 Dec; 15(23):1257-1272. PubMed ID: 38126720
[No Abstract] [Full Text] [Related]
4. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
5. Organochlorine pesticides induce thyroid tumors through oxidative stress; an in vivo and in silico study.
Salimi F; Asadikaram G; Abolhassani M; Pourfarjam Y; Nejad HZ; Abbasi-Jorjandi M; Sanjari M
Environ Sci Pollut Res Int; 2023 Mar; 30(15):45046-45066. PubMed ID: 36697984
[TBL] [Abstract][Full Text] [Related]
6. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.
Mohammadi-asl J; Larijani B; Khorgami Z; Tavangar SM; Haghpanah V; Kheirollahi M; Mehdipour P
Med Oncol; 2011 Dec; 28(4):1123-8. PubMed ID: 20535589
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.
Paydar P; Asadikaram G; Nejad HZ; Akbari H; Abolhassani M; Moazed V; Nematollahi MH; Ebrahimi G; Fallah H
J Cell Biochem; 2019 Aug; 120(8):13726-13736. PubMed ID: 30938887
[TBL] [Abstract][Full Text] [Related]
8. Organochlorine pesticides and risk of papillary thyroid cancer in U.S. military personnel: a nested case-control study.
Rusiecki JA; McAdam J; Denic-Roberts H; Sjodin A; Davis M; Jones R; Hoang TD; Ward MH; Ma S; Zhang Y
Environ Health; 2024 Mar; 23(1):28. PubMed ID: 38504322
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules.
Li M; Yin Y; Zhang M; Jiang C; Li H; Yang R
Horm Metab Res; 2023 Dec; 55(12):869-875. PubMed ID: 38040022
[TBL] [Abstract][Full Text] [Related]
10. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
[TBL] [Abstract][Full Text] [Related]
12. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
13. Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.
Qu M; Wan S; Ren B; Wu H; Liu L; Shen H
Endocrine; 2020 Sep; 69(3):508-515. PubMed ID: 32279226
[TBL] [Abstract][Full Text] [Related]
14. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
15. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic significance of DNA methylation of PTEN and DAPK in thyroid tumors.
Wei F; Wu Y; Wang Z; Li Y; Wang J; Shao G; Yang Y; Shi B
Clin Endocrinol (Oxf); 2020 Aug; 93(2):187-195. PubMed ID: 32286703
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
[TBL] [Abstract][Full Text] [Related]
19. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma.
Zhang S; Wang Y; Chen M; Sun L; Han J; Elena VK; Qiao H
Sci Rep; 2017 Mar; 7():44033. PubMed ID: 28272462
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
